Thromboembolism is a condition in which a blood clot forms in one part of the body, breaks free, and travels through the bloodstream until it lodges in a vessel elsewhere, blocking blood flow. It is one of the leading causes of preventable hospital deaths and a major contributor to stroke, limb damage, and sudden cardiac collapse. The term covers a broad family of events that differ depending on whether the clot lands in the lungs, the brain, or another organ, and the consequences range from barely noticeable to fatal within minutes.
How a Clot Forms and Becomes Dangerous
Blood clotting is a normal, life-saving process. When you cut your skin, proteins and cell fragments called platelets rush to the wound and build a plug to stop bleeding. The problem starts when this same machinery activates inside an intact blood vessel where there is no wound to seal. A framework often used to explain why this happens involves three overlapping conditions: changes in the blood itself that make it clot too easily, damage or dysfunction in the vessel wall, and sluggish or turbulent blood flow.
These three factors, sometimes called Virchow’s triad, rarely act alone. A person who is bedridden after surgery, for example, has slow-moving blood in the legs. If that person also has an inherited tendency toward stickier blood, the combination can be enough to trigger a clot inside a deep leg vein. Damage to the vessel lining from infection, inflammation, or a catheter adds a third push in the same direction.1PubMed Central. Procoagulant activity in hemostasis and thrombosis: Virchow’s triad revisited
A clot sitting in a vein is a deep vein thrombosis, or DVT. It is dangerous on its own because it can swell the limb and damage the surrounding vein valves, but the real emergency comes when part or all of the clot detaches. Once free, the fragment rides the bloodstream back toward the heart and is pumped into the lungs. There, it can wedge itself into a pulmonary artery and partially or completely cut off blood flow to a section of lung tissue. The clot can also fragment mechanically as it passes through the heart chambers and on impact with the vessel wall, meaning pieces can scatter across multiple lung branches at once.2Chest. Pathology of Pulmonary Thromboembolism
Pulmonary Embolism and What It Does to the Heart
A pulmonary embolism, or PE, is the most feared outcome of venous thromboembolism. When a clot blocks a pulmonary artery, pressure in the lung’s blood vessels spikes. The right side of the heart, which is designed to pump against low pressures, suddenly has to work much harder. If the obstruction is large enough, the right ventricle can stretch and weaken, reducing the amount of blood it pushes out with each beat. This cascade of rising pressure, falling output, and impaired heart muscle function can lead to shock and death if not treated quickly.3PubMed Central. Pulmonary Embolism and Right Ventricular Dysfunction: Mechanism and Management
Not every PE is immediately life-threatening. Small emboli that block only minor branches of the pulmonary tree can cause chest pain and shortness of breath but allow the person to remain stable while treatment is started. The danger exists on a spectrum, and clinicians classify PE by how much strain it puts on the heart. Massive PE with low blood pressure and signs of shock sits at the severe end; smaller clots that barely register on imaging sit at the other. Still, even a “small” PE deserves attention because it signals an active clot source that could send a larger fragment at any time.
When Clots Hit the Arteries Instead
The venous system is not the only site where thromboembolism occurs. In the arterial system, the most common scenario involves the heart itself. People with atrial fibrillation, a common irregular heart rhythm, are especially vulnerable. During atrial fibrillation the upper chambers of the heart quiver instead of contracting effectively, and blood pools in a small pouch called the left atrial appendage. This stagnant blood can clot, and if a piece breaks loose, it is pumped straight into the aorta and from there into arteries feeding the brain, kidneys, intestines, or limbs.4PubMed. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study)
More than nine out of ten embolic strokes linked to atrial fibrillation trace back to clots formed in the left atrial appendage.5PubMed Central. Association Between Left Atrial Appendage Morphology and Function and the Risk of Ischaemic Stroke in Patients with Atrial Fibrillation Hemodynamic studies have confirmed the mechanism: people who go on to have strokes tend to have slower, more swirling blood flow inside the appendage, creating conditions that favor clot formation.6Heliyon. Patient-specific hemodynamic and geometric assessment of left atrium and left atrial appendage to evaluate stroke risk in paroxysmal atrial fibrillation patients This is why anticoagulant therapy is so central to managing atrial fibrillation: the arrhythmia itself is rarely deadly, but the strokes it causes can be devastating.
Paradoxical Embolism and Hidden Heart Defects
There is a less common but striking scenario in which a venous clot ends up in the arterial system without passing through the lungs. About one in four people are born with a patent foramen ovale, a small flap-like opening between the right and left upper chambers of the heart that usually closes after birth but in some people remains partially open. If pressure on the right side of the heart rises, as happens during a pulmonary embolism, coughing, or straining, blood can briefly shunt from right to left through that opening. A clot riding that shunt bypasses the lungs entirely and enters the arterial circulation, where it can cause a stroke or block an artery in a limb or organ.
This phenomenon is called paradoxical embolism. A patent foramen ovale accounts for roughly five to ten percent of all paradoxical emboli, and deep vein thrombosis is the main source of the traveling clot.7Journal of Vascular Surgery Cases, Innovations and Techniques. Paradoxical embolism via patent foramen ovale induced by deep venous thrombosis and acute pulmonary embolism Paradoxical embolism is often diagnosed only after a young person has a stroke with no obvious cardiac risk factors, prompting a search for an intracardiac shunt.
Why Some People Clot More Easily Than Others
Thromboembolism is not purely bad luck. A web of inherited and acquired risk factors determines how prone any individual is. On the genetic side, the most common inherited predisposition involves a mutation in factor V, one of the proteins in the clotting cascade. The variant, known as factor V Leiden, makes the protein resistant to a natural anticoagulant system, tipping the balance toward excessive clotting.8PubMed. Factor V Leiden and hemophilia Carriers of one copy of the mutation have a moderately elevated risk; carriers of two copies face a much higher risk. Other inherited conditions, such as prothrombin gene mutations and deficiencies in proteins C or S, work through different steps in the same cascade but produce a similar net result: blood that clots too readily.
Among acquired risk factors, cancer stands out. Tumors can release tiny membrane-bound particles into the bloodstream carrying tissue factor, a protein that kickstarts the clotting process. These circulating particles may explain why certain cancers, particularly those of the pancreas, brain, and ovary, carry an especially high rate of thromboembolism.9PubMed Central. Novel Aspects of Extracellular Vesicles as Mediators of Cancer-Associated Thrombosis 10PubMed Central. Extracellular vesicles, tissue factor, cancer and thrombosis – discussion themes of the ISEV 2014 Educational Day In fact, an unexplained DVT or PE is sometimes the first clue that a malignancy is present, prompting physicians to consider screening in patients who develop clots without any obvious trigger.
Pregnancy, hormone therapy, obesity, prolonged immobility after surgery, and certain anatomical quirks also push risk upward. May-Thurner syndrome, for instance, is a condition in which the right iliac artery compresses the left iliac vein in the pelvis, slowing blood flow and predisposing to DVT in the left leg. In pregnant patients the syndrome can be aggravated by the weight of the uterus and by the natural shift toward easier clotting that occurs during pregnancy.11PubMed Central. Management of May Thurner Syndrome in Pregnant Patients
Travel, Sitting, and the “Economy Class Syndrome” Myth
The idea that a long flight can cause a deadly blood clot has been embedded in public awareness since the term “economy class syndrome” was coined decades ago. The reality is more nuanced. A systematic review pooling data from studies of air travel and DVT found no definitive evidence that flights of three hours or more increase the risk of DVT on their own. The pooled odds for DVT after general air travel were close to baseline. However, there was a suggestion that flights of eight hours or more raise the risk when other factors, such as obesity, recent surgery, or an inherited clotting tendency, are already present.12PubMed Central. The association between air travel and deep vein thrombosis: Systematic review & meta-analysis
The takeaway is that sitting motionless for many hours is the real issue, not the airplane specifically. Long car rides and train journeys carry the same concern. If you are otherwise healthy and have no inherited clotting issues, a transatlantic flight is unlikely to cause a DVT by itself. But if you are overweight, on estrogen-containing hormones, recovering from surgery, or know you carry a clotting mutation, staying hydrated, getting up periodically, and wearing compression stockings during very long trips is a sensible precaution.
How Thromboembolism Is Diagnosed
Clinicians face a tricky balance when evaluating a possible DVT or PE. The symptoms, leg swelling for DVT, chest pain and breathlessness for PE, overlap with many other conditions. A simple blood test for a substance called D-dimer is often the first step. D-dimer is a protein fragment released when a blood clot dissolves, so elevated levels suggest a clot may be present. A systematic review of D-dimer tests found that the most sensitive assay types are very good at ruling out thromboembolism: if the test comes back negative, the probability that a clot is actually there is very low.13PubMed. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review The trade-off is that these sensitive tests produce many false positives. Inflammation, surgery, pregnancy, cancer, and even older age can all raise D-dimer without any clot, which means a positive result usually needs confirmation with imaging.
In practice, physicians combine a clinical probability assessment with the D-dimer result. If your doctor judges you to be at low risk and the D-dimer is negative, DVT can be ruled out without an ultrasound.14PubMed. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis If either the clinical suspicion or the D-dimer is elevated, ultrasound of the legs (for suspected DVT) or CT angiography of the chest (for suspected PE) follows. These imaging tests are highly accurate and give clinicians a direct look at the clot’s size and location.
Treatment and the Shift Away from Warfarin
Anticoagulant drugs remain the backbone of thromboembolism treatment. For decades warfarin was the standard oral anticoagulant, but it requires frequent blood monitoring and interacts with dozens of foods and medications. A newer class of drugs, the direct oral anticoagulants, has largely replaced warfarin for most patients with venous thromboembolism. A large observational study of nearly sixty thousand patients found that the risk of major bleeding was similar between the newer agents and warfarin, with the overall direction slightly favoring the newer drugs, and death rates were virtually identical.15BMJ. Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study The practical advantage is convenience: the newer drugs are taken at fixed doses without routine blood tests, making them easier for patients to stick with.
For severe or life-threatening PE, drug therapy alone sometimes is not fast enough. Catheter-based treatments allow physicians to thread a thin tube through the blood vessels directly to the clot and either dissolve it with a concentrated dose of clot-busting medication or physically break it apart and remove the fragments. These procedures can produce rapid improvement in patients whose hearts are failing under the strain of a massive embolism, though they are still available mainly at specialized centers.16EuroIntervention. Catheter-based techniques for pulmonary embolism treatment
A Paradox in Heparin Treatment
One of the more counterintuitive complications in thromboembolism management involves heparin, the injectable anticoagulant used in hospitals to prevent and treat clots. In a small percentage of patients, the immune system produces antibodies against a complex of heparin and a platelet protein. These antibodies activate platelets rather than quieting them, leading to a condition in which platelet counts drop while new clots form aggressively. Despite the low platelet count, bleeding is rare; instead, patients face a surging risk of both arterial and venous clots.17PubMed Central. Heparin induced thrombocytopenia: diagnosis and management update Recognizing this reaction quickly and switching to an alternative anticoagulant is critical, because continuing heparin only worsens the problem.
Life After a Clot
Surviving a DVT or PE does not always mean a clean return to normal. Between a fifth and half of DVT patients develop post-thrombotic syndrome, a chronic condition in which the affected leg remains swollen, achy, and prone to skin changes. In five to ten percent of cases the outcome is severe enough to include open ulcers on the leg that are difficult to heal. The biggest risk factors for this complication are a large initial clot, a repeat DVT in the same leg, persistent symptoms a month after the acute event, obesity, and older age.18PubMed Central. The post-thrombotic syndrome
In the lungs, a similar long-term consequence can occur. If PE material does not fully dissolve, scar tissue can organize inside the pulmonary arteries and permanently narrow them. Over months to years this raises lung artery pressure chronically, a condition called chronic thromboembolic pulmonary hypertension. It causes progressive breathlessness and exercise intolerance, and when it does develop, it can require specialized surgery or targeted medication to manage.19PubMed Central. Pulmonary Embolism and Right Ventricular Dysfunction: Mechanism and Management
Prevention in Hospitals
Because immobility after surgery or during a hospital stay is one of the strongest triggers for DVT, prevention is standard care for many inpatients. The two main approaches are blood-thinning drugs given at low “prophylactic” doses and mechanical compression devices that squeeze the legs rhythmically to keep blood moving.
A meta-analysis of randomized trials looked at how well intermittent pneumatic compression devices prevent DVT in surgical patients. Compared to no prevention at all, the devices cut DVT risk substantially. However, when compared head-to-head with drug prophylaxis alone, the devices showed no statistically significant advantage or disadvantage. And patients who received both devices and drugs together did no worse than those with devices alone, though the trend favored the combination.20PLOS ONE. Effects of intermittent pneumatic compression devices interventions to prevent deep vein thrombosis in surgical patients: A systematic review and meta-analysis of randomized controlled trials In practice, patients who cannot take blood thinners because of bleeding risk are given compression devices as an alternative, and those at very high risk often receive both.
Where the Immune System Meets Clotting
A rapidly growing area of research explores the overlap between the immune system and clot formation. White blood cells called neutrophils, best known for fighting bacteria, can expel webs of DNA and proteins into the bloodstream when stimulated by inflammation. These webs, called neutrophil extracellular traps, catch pathogens but also trap platelets and clotting factors, promoting thrombosis.21PubMed Central. Neutrophil extracellular traps mediate neuro-immunothrombosis This process, termed immunothrombosis, helps explain why severe infections, autoimmune flares, and systemic inflammation so frequently coincide with clotting events. It also may partly account for the high rate of thromboembolism observed during severe COVID-19, though the full picture of that connection is still being studied.
Next-Generation Anticoagulants and the Dream of Bleed-Free Treatment
Every existing anticoagulant works by dampening parts of the clotting system that are also involved in stopping normal bleeding. That is why all current therapies carry a risk of hemorrhage, the most serious side effect of treatment. Researchers have been searching for targets in the clotting cascade that contribute to clot formation inside blood vessels but play little role in sealing wounds.
Two proteins in particular have attracted attention: factor XI and factor XII. In animal models, removing either protein significantly reduced clot formation without causing major bleeding problems. Clinical observations support the idea: people born without factor XII do not bleed at all, and those without factor XI rarely experience spontaneous bleeding while appearing to be partly protected from clots.22PubMed Central. Factor XI and XII as antithrombotic targets 23PubMed. Factor XI and factor XII as targets for new anticoagulants Several drugs targeting factor XI are now in clinical trials. If they live up to their early promise, they could fundamentally change how thromboembolism is treated by offering potent clot prevention without the constant worry about bleeding complications.
Why Humans Are Especially Vulnerable
It is worth stepping back and noticing something that is easy to take for granted: thromboembolism in the leg veins is overwhelmingly a human problem. Four-legged animals rarely develop spontaneous DVT. The reason lies in evolutionary biomechanics. When humans began walking upright, gravity gained enormous leverage over the blood pooling in the lower body. In quadrupeds, blood pressure regulation is dominated by reflexes tuned to handle hemorrhage. In humans, a different reflex system, one that monitors low-pressure areas like the veins returning blood to the heart, was repurposed to manage the unique challenge of standing.24Journal of Hypertension. Consequences of the evolutionary cardiovascular challenge of human bipedalism Despite that adaptation, venous blood still pools in the calves when you stand or sit for long periods. The valves in the leg veins and the pumping action of calf muscles during walking counteract this pooling, but when those defenses falter, the conditions for clot formation emerge. In a sense, DVT is a tax we pay for walking on two legs.